Phase 3 clinical trial: Brain cancer vaccine shows promising results


A vaccine (DCVax-L), trialed at King’s College Hospital and other centers around the world, using patients’ immune cells to target brain cancer can extend survival by many months or, in some cases, years, the final unblinded results from a phase 3 clinical trial has shown. The final results were published on Thursday, November 17 in JAMA Oncology.

You can run this tiny 3D printer off a powerbank

Previous article

Lab mice fed processed food found to fare worse against flu than those eating grains

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations